Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind randomized withdrawal study evaluating the efficacy and safety of SR58611A [amibegron] versus placebo in the prevention of relapse of anxiety up to 1 year in patients with GAD [generalised anxiety disorder] improved after 12 weeks of open label treatment with SR58611A

Next Previous
X
Search
Trial Profile

A double-blind randomized withdrawal study evaluating the efficacy and safety of SR58611A [amibegron] versus placebo in the prevention of relapse of anxiety up to 1 year in patients with GAD [generalised anxiety disorder] improved after 12 weeks of open label treatment with SR58611A

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amibegron (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Acronyms VEGA
  • Sponsors Sanofi

    • Most Recent Events

    • 02 Sep 2021 This trial has been completed in Spain (Global End Date: 19 Sep 2007).
    • 07 Jul 2009 Actual patient number (257) added as reported by ClinicalTrials.gov.
    • 25 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top